Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for IBS and SIBO
NCT00259155Phase 2Completed
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Jul 2003
- Primary completion
- Jan 2007
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of rifaximin in irritable bowel syndrome (IBS), small intestinal bacterial overgrowth (SIBO), sponsored by Cedars-Sinai Medical Center. Started Jul 2003; status: completed.
02
Drugs
rifaximin
03
Conditions
irritable bowel syndrome (IBS)small intestinal bacterial overgrowth (SIBO)
Beyond the preview
Go deeper on NCT00259155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00259155.